Atrium Therapeutics prices $50 million private placement at $7.93 per share
RNA•Atrium Therapeutics priced a $50 million private placement, including 5,170,384 shares at $7.93 each and pre-funded warrants for 1,134,930 shares at $7.929, with closing expected on or about Oct. 9, 2026.
1. Placement details
Atrium Therapeutics priced an unregistered $50 million private placement, expected to close on or about Oct. 9, 2026. The company plans to use proceeds for its lead RNA cardiology programs, other research, working capital and general corporate purposes, and projected its cash runway through 2028.
